C4 Therapeutics, Inc. (NASDAQ:CCCC) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants, each with a Class A Warrant and a Class B Warrant Announced: US$125M–US$349.7M · US$2.47 a share · Warrants at US$2.22 · Jefferies +2 Dealers: Jefferies (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead) Buyers: RA Capital Management (led the offering); OrbiMed; Soleus Capital; Lynx1 Capital Management; Bain Capital Life Sciences Use of proceeds: Fund ongoing and planned clinical trials of cemsidomide, other R&D, working capital and general corporate purposes | Oct 16, 2025 |